Cancer News and Research

Latest Cancer News and Research

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune.

7 Jan 2012

Employees at Virginia Commerce Bank complete 12-week 'Stepitup' fitness program

Virginia Commerce Bank employees recently stepped up their game by completing a company-wide walking program that encouraged fitness and overall wellness. The 12-week fitness program, named "Stepitup," utilized pedometers to track employees' steps and offered incentives for participation and for meeting minimum walking goals.

7 Jan 2012

Major tobacco company manipulates data on effects of additives in cigarettes

A new UCSF analysis of tobacco industry documents shows that Philip Morris USA manipulated data on the effects of additives in cigarettes, including menthol, obscuring actual toxicity levels and increasing the risk of heart, cancer and other diseases for smokers.

7 Jan 2012

Smokeless tobacco products in India associated with increased risk of oral cancer

The 2nd International Conference on the Frontiers in Prevention, Diagnosis & Therapy of Cancer was held on 7th Jan. 2012 at Allahabad, India and looked at the relationship of oral cancer with tobacco habits. Various innovations in oral cancer diagnosis, therapy and tobacco usage were discussed by experts from around the world.

7 Jan 2012

Prospective surveillance model can reduce treatment costs for breast cancer-related lymphedema

Early diagnosis and treatment of breast cancer-related lymphedema by a physical therapist can significantly reduce costs and the need for intensive rehabilitation, according to an article published in the January issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association.

7 Jan 2012

Drinking red wine in moderation may reduce risk of breast cancer

Drinking red wine in moderation may reduce one of the risk factors for breast cancer, providing a natural weapon to combat a major cause of death among U.S. women, new research from Cedars-Sinai Medical Center shows.

7 Jan 2012

Annual prostate cancer testing does not reduce mortality among men

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

7 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

SPIE to honor CCNY professor with Britton Chance Biomedical Optics Award

A scientific innovator from The City College of New York (CCNY) whose research unites the divergent fields of medicine, biology and high-speed laser physics will be honored this month for his pioneering work in biomedical optics by SPIE, the international society for optics and photonics.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

VisionGate achieves full automation of Cell-CT system

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

FDA approval of raltegravir offers new weapon to treat HIV infection in children

For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.

7 Jan 2012

Synta prices underwritten public offering of 7,000,000 shares of common stock

Synta Pharmaceuticals Corp. announced today that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per share.

7 Jan 2012

Third Security, Transgenomic enter Convertible Promissory Note Purchase Agreement

Transgenomic, Inc. today announced that it has entered into a Convertible Promissory Note Purchase Agreement in the aggregate amount of $3.0 million with entities associated with Third Security, LLC, a leading life sciences investment firm.

7 Jan 2012

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012

Roundup: Miami police unions thwart health premiums increase; Washington's mandatory-abortion-coverage bill

Despite blunt warnings from Mayor Carlos Gimenez that their decision would force layoffs of hundreds of police and corrections officers, Miami-Dade commissioners Thursday narrowly refused to force two employee unions to contribute an additional 5 percent of their pay toward health insurance. ... The panel also refused to impose the controversial 5-percent giveback on its professionals and supervisor.

6 Jan 2012

First Edition: January 6, 2012

In today's news, reports from the campaign trail and details about how nine states have asked the federal government for more funding to make sure their high-risk pools don't run out of cash before 2014.

6 Jan 2012

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash and common stock, subject to the achievement of specific sales and earnings targets.

6 Jan 2012